Our team is here to support your journey, helping you achieve consistent, sustainable results and lasting improvements in health and confidence
Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound
AOD 9604 has no effect on glucose metabolism
Retatrutide produced substantial placebo-adjusted weight loss across all doses, ranging from 19.0% to 28.3%, compared with 2.2% with placebo
You may be a candidate for semaglutide if you are clinically overweight or obese, have struggled to lose weight through diet and exercise alone, and do not have medical conditions that would prevent treatment
it's about whether the delivery method bypasses the digestive hurdles that usually block absorption